Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
OPERATING ACTIVITIES    
Net (loss) income $ (395) $ 111
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Provision for doubtful accounts (194) 47
Depreciation 5,438 5,801
Loss on disposal of and reserve adjustments for medical equipment 316 828
Gain on sale of medical equipment (1,036) (1,402)
Amortization of intangible assets 495 495
Amortization of deferred debt issuance costs 39 78
Stock-based compensation 2,055 1,736
Deferred income taxes 405 (106)
Changes in assets - (increase)/decrease:    
Accounts receivable (1,203) (506)
Inventories (437) (885)
Other current assets (446) (994)
Other assets 914 (1,719)
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (3,265) (1,183)
NET CASH PROVIDED BY OPERATING ACTIVITIES 2,686 2,301
INVESTING ACTIVITIES    
Purchase of medical equipment (8,796) (6,994)
Purchase of property and equipment (519) (494)
Proceeds from sale of medical equipment, property and equipment 2,201 2,098
NET CASH USED IN INVESTING ACTIVITIES (7,114) (5,390)
FINANCING ACTIVITIES    
Principal payments on long-term debt (26,744) (29,451)
Cash proceeds from long-term debt 31,769 32,585
Debt issuance costs 0 (229)
Common stock repurchased as part of share repurchase program (283) (153)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (624) (523)
Cash proceeds from exercise of options and ESPP 225 829
NET CASH PROVIDED BY FINANCING ACTIVITIES 4,343 3,058
Net change in cash and cash equivalents (85) (31)
Cash and cash equivalents, beginning of period 231 165
Cash and cash equivalents, end of period $ 146 $ 134